Moderna management check

MRNA · Health Care · Biotechnology · CEO Stephane Bancel

Filings as of

53
Management score, ranked 405th of 487 · 50th of 60 in Health Care4 good · 0 to watch · 3 flaggedStrongest: clean books · Weakest: CEO cost · Best and worst run in Health Care →

The seven checks

  • Flag

    Have owners done well?

    Trailed its chosen peersOwners$28Peers$120

    What $100 became since fiscal 2021

    016th
    Detail

    $100 invested at the start of fiscal 2021 grew to $28, against $120 for the peer group the company picked itself.

  • Good

    Does pay follow performance?

    Pay rose and fell with returns20212025

    Pay actually paid $100 value, each on its own scale

    7741st
    Detail

    Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.55 with shareholder return. 1 means pay moved in step; below 0, the opposite way.

  • Flag

    What does the CEO cost owners?

    Paid in a loss-making year

    $19.9m pay · −$2.8bn net income, FY2025

    0.1%1%3%10%loss
    016th
    Detail

    $19.9m of reported pay in fiscal 2025, a year the company lost $2.8bn.

  • Good

    Do they own the stock?

    CEO stake ≈ 6.4 years of pay

    6,687,037 shares ≈ $128.1m

    0.1y1y5y20y100y

    6 mo: ▲ $0 bought · ▼ $86.4m sold

    7576th
    Detail

    The CEO holds 6,687,037 shares, directly or through trusts (unvested awards not counted): about 6.4 years of pay. Light activity: no buys, $86.4m sold in six months. 19 of 20 sales ran on pre-arranged 10b5-1 plans.

  • Flag

    Are owners being diluted?

    Share count growing2021 · 431m2025 · 389m

    Diluted shares +0.9% a year; flagged above +2%

    0%10%20%

    Stock pay 24.8% of revenue

    2014th
    Detail

    Diluted shares changed +0.9% a year over the last three fiscal years. Stock-based pay was 24.8% of revenue in the latest year.

  • Good

    Is leadership stable?

    6 leadership filings in 3 years

    6 filings under 8-K 5.02 in 3 years

    0101420+

    CEO: Mr. Bancel

    9575th
    Detail

    CEO in the pay table: Mr. Bancel. 6 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.

  • Good

    Are the books clean?

    No red flags on file

    Since 2021

    • 0Restated
    • 0Auditor changes
    • 0Late filings
    • 010-K amended
    100100th
    Detail

    No restatements, auditor changes or late filings since 2021.

  • Reading the scores

    Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.

    Hover a chart for its figures. Detail has the full reading.

Pay versus performance

From the proxy statement filed March 16, 2026.

CEO pay as reportedActually paid ⓘWhat $100 becamePeer group the company chose
−$306.2m$243.4m$793.0m$10020212022202320242025$28$120

Pay tied most to Total Revenue

Other key measuresOperating ExpenseTotal Shareholder Return (TSR)

Show the figures
Fiscal yearCEOCEO payActually paidOther executives (avg)$100 becamePeersNet income
2025Mr. Bancel$19.9m$15.8m$9.8m$28$120−$2.8bn
2024Mr. Bancel$19.9m$5.8m$14.6m$40$91−$3.6bn
2023Mr. Bancel$17.1m−$155.6m$5.1m$95$92−$4.7bn
2022Mr. Bancel$19.4m−$306.2m$5.8m$172$89$8.4bn
2021Mr. Bancel$18.2m$793.0m$8.3m$243$99$12.2bn

Insiders and the CEO's stakeQuiet

Chief Executive Officer
Stephane Bancel
Shares held
6,687,037
At that filing's price
≈ $128.1m
Latest Form 4
Aug 6, 2026

Light activity: no buys, $86.4m sold in six months. 19 of 20 sales ran on pre-arranged 10b5-1 plans.

Open-market trades by officers and directors since May 21, 2026.

  • SoldStephen HogePresident · 10b5-1 plan$52.0mNov 17, 2026
  • SoldStephane BancelChief Executive Officer · 10b5-1 plan$28.7mAug 5, 2026
  • SoldJames M MockChief Financial Officer · 10b5-1 plan$4.7mSep 10, 2026
  • SoldShannon Thyme KlingerChief Legal Officer · 10b5-1 plan$659kSep 1, 2026

Leadership and governance on file

20222023202420252026Leadership 12Votes 6
All 12 filings

Latest shareholder vote results: May 11, 2026, including the say-on-pay vote.

Where the money went

2021–2025: $5.3bn returned to owners in buybacks and dividends, 56% of net income, and $1.6bn of pay in stock.

Net incomeBuybacksDividendsStock-based payDiluted shares
−$4.7bn$3.7bn$12.2bn20212022202320242025Shares431m416m382m384m389m
Show the figures
Fiscal year20212022202320242025
Revenue$18.5bn$19.3bn$6.8bn$3.2bn$1.9bn
Net income$12.2bn$8.4bn−$4.7bn−$3.6bn−$2.8bn
Stock-based pay$142.0m$226.0m$305.0m$429.0m$483.0m
Buybacks$857.0m$3.3bn$1.2bn$0$2.0m
Dividends—————
Diluted shares431m416m382m384m389m

Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.